Browse > Article
http://dx.doi.org/10.14348/molcells.2016.2267

Acetylation Enhances the Promoting Role of AIB1 in Breast Cancer Cell Proliferation  

You, Dingyun (Kunming Medical University)
Zhao, Hongbo (Institute of Molecular and Clinical Medicine)
Wang, Yan (The second Affiliated Hospital of Kunming Medical University)
Jiao, Yang (Institute of Molecular and Clinical Medicine)
Lu, Minnan (Experiment Center for Medical Science Research, Kunming Medical University)
Yan, Shan (Institute of Molecular and Clinical Medicine)
Publication Information
Molecules and Cells / v.39, no.9, 2016 , pp. 663-668 More about this Journal
Abstract
The oncogene nuclear receptor coactivator amplified in breast cancer 1 (AIB1) is a transcriptional coactivator, which is overexpressed in various types of human cancers, including breast cancer. However, the molecular mechanisms regulating AIB1 function remain largely unknown. In this study, we present evidence demonstrating that AIB1 is acetylated by MOF in human breast cancer cells. Moreover, we also found that the acetylation of AIB1 enhances its function in promoting breast cancer cell proliferation. We further showed that the acetylation of AIB1 is required for its recruitment to E2F1 target genes by E2F1. More importantly, we found that the acetylation levels of AIB1 are greatly elevated in human breast cancer cells compared with that in non-cancerous cells. Collectively, our results shed light on the molecular mechanisms that regulate AIB1 function in breast cancer.
Keywords
acetylation; AIB1; breast cancer; E2F1; MOF;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Albertson, D.G. (2006). Gene amplification in cancer. Trends Genet. 22, 447-455.   DOI
2 Anzick, S.L., Kononen, J., Walker, R.L., Azorsa, D.O., Tanner, M.M., Guan, X.Y., Sauter, G., Kallioniemi, O.P., Trent, J.M., and Meltzer, P.S. (1997). AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science 277, 965-968.   DOI
3 Bautista, S., Valles, H., Walker, R. L., Anzick, S., Zeillinger, R., Meltzer, P., and Theillet, C. (1998). In breast cancer, amplification of the steroid receptor coactivator gene AIB1 is correlated with estrogen and progesterone receptor positivity. Clin. Cancer Res. 4. 2925-2929.
4 Easton, D.F., Bishop, D.T., Ford, D., and Crockford, G.P. (1993). Genetic linkage analysis in familial breast and ovarian cancer:results from 214 families. The Breast Cancer Linkage Consortium. Am. J. Hum Genet. 52, 678-701.
5 Hortobagyi, G.N. (1998). Treatment of breast cancer. New Engl. J. Med. 339, 974-984.   DOI
6 Kranzfelder, M., Schuster, T., Geinitz, H., Friess, H., and Buchler, P. (2011). Meta‐analysis of neoadjuvant treatment modalities and definitive non‐surgical therapy for oesophageal squamous cell cancer. Brit. J. Surg. 98, 768-783.   DOI
7 Livak K.J., and Schmittgen T.D. (2001). Analysis of relative gene expression data using real-time quantitative PCR and the $2-^{{\Delta}{\Delta}Ct}$ method. Methods 25, 402-408.   DOI
8 Louie, M.C., Zou, J.X., Rabinovich, A., and Chen, H.W. (2004). ACTR/AIB1 functions as an E2F1 coactivator to promote breast cancer cell proliferation and antiestrogen resistance. Mol. Cell Biol. 24, 5157-5171.   DOI
9 Mavaddat, N., Pharoah, P.D., Blows F., Driver, K.E., Provenzano, E., Thompson, D., Macinnis, R.J., Shah, M., Easton, D.F., and Antoniou, A.C. (2010). Familial relative risks for breast cancer by pathological subtype: a population-based cohort study. Breast Cancer Res. 12, R10.   DOI
10 McPherson, K., Steel, C. and Dixon, J. (2000). ABC of breast diseases: breast cancer-epidemiology, risk factors, and genetics. BMJ-Brit. Med. J. 321, 624.   DOI
11 Miki, Y., Swensen, J., Shattuck-Eidens. D., Futreal, P.A., Harshman, K., Tavtigian, S., Liu, Q., Cochran, C., Bennett, L.M., Ding, W., et al. (1994). A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266, 66-71.   DOI
12 Parkin, D. M., Bray, F., Ferlay, J., and Pisani, P. (2005). Global cancer statistics, 2002. CA-Cancer J. Clin. 55, 74-108.   DOI
13 Sakaguchi, H., Fujimoto, J., Sun, W.S., and Tamaya, T. (2007). Clinical implications of steroid receptor coactivator (SRC)-3 in uterine endometrial cancers. J. Steroid Biochem. Mol. Biol. 104, 240.
14 Santarius, T., Shipley, J., Brewer, D., Stratton, M.R., and Cooper, C.S. (2010). A census of amplified and overexpressed human cancer genes. Nat. Rev. Cancer 10, 59-64.   DOI
15 Thompson, D., and Easton, D. (2004). The genetic epidemiology of breast cancer genes. J. Mammary Gland. Biol. 9, 221-236.   DOI
16 Weigelt, B., Peterse, J.L., and van't Veer, L.J. (2005). Breast cancer metastasis: markers and models. Nat. Rev. Cancer 5, 591-602.   DOI
17 Werbajh, S., Nojek, I., Lanz, R., and Costas, M.A. (2000). RAC-3 is a NF-kappa B coactivator. FEBS Lett. 485, 195-199.   DOI
18 Wooster, R., Bignell, G., Lancaster, J., Swift, S., Seal, S., Mangion, J., Collins, N., Gregory, S., Gumbs, C., and Micklem, G. (1995). Identification of the breast cancer susceptibility gene BRCA2. Nature 378, 789-792.   DOI
19 Zhou, H.J., Yan, J., Luo, W., Ayala, G., Lin, S.H., Erdem, H., Ittmann, M., Tsai, S.Y., and Tsai, M.J. (2005). SRC-3 is required for prostate cancer cell proliferation and survival. Cancer Res. 65, 7976-7983.   DOI
20 Yan, J., Yu, C.T., Ozen, M., Ittmann, M., Tsai, S.Y., and Tsai, M.J. (2006). Steroid receptor coactivator-3 and activator protein-1 coordinately regulate the transcription of components of the insulinlike growth factor/AKT signaling pathway. Cancer Res. 66, 11039-11046.   DOI